课题基金 / 基金详情

EFFICACY AND SAFETY OF MIBEFRADIL W/ VERAPAMIL IN MILD TO MODERATE HYPERTENSION

EFFICACY AND SAFETY OF MIBEFRADIL W/ VERAPAMIL IN MILD TO MODERATE HYPERTENSION
米贝拉地尔联合维拉帕米治疗轻至中度高血压的疗效和安全性
批准号：
6119094
负责人：
BRENT M EGAN
金额：
$1.74万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6119094
关键词：
calcium channel blockers cardiovascular disorder chemotherapy clinical research clinical trials combination chemotherapy drug screening /evaluation human subject human therapy evaluation hypertension vasodilators verapamil

项目摘要

项目成果

BRENT M EGAN的其他基金

相关文献

中文摘要
翻译
比较两组患者积极治疗8周后平均坐位舒张压(SDBP)的变化。积极治疗8周后平均坐位收缩压(SSBP)的变化。积极治疗4周后观察平均坐位舒张压(SDBP)的变化。积极治疗4周后观察平均坐位收缩压(SSBP)的变化。描述各治疗组的正确率和有效率。通过监测不良事件和心率，描述米贝弗地尔与维拉帕米缓释片的安全性。
英文摘要
To evaluate the differences between treatment groups in: The change of mean trough sitting diastolic blood pressure (SDBP) after 8 weeks of active treatment. The change of mean trough sitting systolic blood pressure (SSBP) after 8 weeks of active treatment. The change of mean trough sitting diastolic blood pressure (SDBP) after 4 weeks of active treatment. The change of mean trough sitting systolic blood pressure (SSBP) after 4 weeks of active treatment. To describe the mormalization rate and the response rate for each treatment group. To describe safety of mibefredil with that of verapamil SR through monitoring of adverse events and heart rate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study
PROTEOMIC ANALYSIS OF BLOOD: ZN-ALPHA-2-GLYCOPROTEIN AS A BIOMARKER FOR CACHE
FATTY ACIDS, ANGIOTENSIN AND OXIDATIVE STRESS